In July 2018, Petrovax Pharm received Marketing Authorization No. LP-004951 for Grippol® Quadrivalent, a 4-valent inactivated subunit adjuvanted vaccine designed for prevention of influenza. It is the most advanced flu vaccine in the world that employs an antigen sparing technology and has a high preventive activity and safety.

The rating is put together annually by Extel, a British company that studies the global investment climate.

This year the Sport Connect Forum, organized by Interros Group and the Russian International Olympic Committee, gathered more than three hundred attendees from the sports industry. The main themes were Global Market Changes and Best Local Projects.